Atai Beckley N.V.ATAIEarnings & Financial Report
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
ATAI Q3 FY2025 Key Financial Metrics
Revenue
$749.0K
Gross Profit
N/A
Operating Profit
$-28.4M
Net Profit
$-61.1M
Gross Margin
N/A
Operating Margin
-3796.5%
Net Margin
-8154.1%
YoY Growth
1772.5%
EPS
$-0.28
Atai Beckley N.V. Q3 FY2025 Financial Summary
Atai Beckley N.V. reported revenue of $749.0K (up 1772.5% YoY) for Q3 FY2025, with a net profit of $-61.1M (down 132.3% YoY) (-8154.1% margin).
Key Financial Metrics
| Total Revenue | $749.0K |
|---|---|
| Net Profit | $-61.1M |
| Gross Margin | N/A |
| Operating Margin | -3796.5% |
| Report Period | Q3 FY2025 |
Atai Beckley N.V. Annual Revenue by Year
Atai Beckley N.V. annual revenue history includes year-by-year totals (for example, 2024 revenue was $308.0K).
Atai Beckley N.V. Quarterly Revenue & Net Profit History
Atai Beckley N.V. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $749.0K | +1772.5% | $-61.1M | -8154.1% |
| Q2 FY2025 | $719.0K | +163.4% | $-27.7M | -3856.6% |
| Q1 FY2025 | $1.6M | — | $-26.4M | -1699.7% |
| Q4 FY2024 | $-5.0K | -127.8% | $-39.0M | 779160.0% |
| Q3 FY2024 | $40.0K | -54.0% | $-26.3M | -65715.0% |
| Q2 FY2024 | $273.0K | +58.7% | $-57.3M | -20993.4% |
| Q1 FY2024 | $0 | — | $-26.7M | N/A |
| Q4 FY2023 | $18.0K | -53.8% | N/A | N/A |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18000 | $0 | $273000 | $40000 | $-5000 | $1.6M | $719000 | $749000 |
| YoY Growth | -53.8% | N/A | 58.7% | -54.0% | -127.8% | N/A | 163.4% | 1772.5% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $293.5M | $269.1M | $215.8M | $197.5M | $159.4M | $195.8M | $189.2M | $239.8M |
| Liabilities | $49.2M | $45.9M | $47.2M | $51.2M | $42.8M | $43.5M | $45.3M | $79.9M |
| Equity | $243.0M | $222.5M | $167.9M | $145.7M | $116.3M | $152.1M | $143.7M | $159.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-84.1M | $-22.6M | $-16.2M | $-19.3M | $-24.3M | $-17.8M | $-14.1M | $-23.3M |